This Phase I award offers Avaxia a sum of around $145,000 in research and development funds.
Avaxia founder and CEO Barbara Fox said they are delighted to have been awarded this grant from the NIH in recognition of the potential of the novel approach to the treatment of celiac disease.
"This NIH support provides the funding we need to advance the development of our anti-gluten antibody into pre-clinical models of celiac disease," Fox said.